“It is vital that policymakers reform Medicare to ensure that seniors receive the full value of low-cost generics and the full value of their Part D benefit,” said Dan Leonard, president and CEO of the US Association for Accessible Medicines, as he pointed out that the latest AAM-sponsored study by researcher Avalere Health has highlighted the continued worsening of generic drug coverage in Medicare Part D.
Generics Coverage In Medicare Part D Plans Worsens In 2021
Generic prescription drugs are only placed on generic tiers 45% of the time in 2021, a significant decrease from the 64% seen in 2016, according to the latest AAM-sponsored study by Avalere Health. AAM is urging policymakers to initiate Medicare Part D reforms.
More from Medicare
• By
Manufacturers have supported the proposed shift in oversight authority, which could create a more pharma-friendly environment in the drug discount program, but uncertainty remains.
• By
No mass exodus was seen from stand-alone prescription drug plans to Medicare Advantage drug plans between 2024 and 2025, according to one actuary.
• By
The preliminary budget document supports legislation clawing back funds appropriated for the program.
• By
Wide-ranging executive order to lower drug prices also hints at changes in upcoming guidance on the Medicare price negotiation program but few other potentially impactful near-term actions.
More from Government Payers
• By
Mechanisms in the draft treaty that the more than 190 member states of the World Health Organization have finally agreed to are expected to “materially affect companies,” particularly those that develop, manufacture or distribute pandemic-related health care products.
• By
The preliminary budget document supports legislation clawing back funds appropriated for the program.
• By
Wide-ranging executive order to lower drug prices also hints at changes in upcoming guidance on the Medicare price negotiation program but few other potentially impactful near-term actions.